Cardiac and renal protective effects of dexmedetomidine in cardiac surgeries

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

PACTR

Registry ID

PACTR201507000984471

Enrollment

Registered

2014-12-28

Start date

2012-06-11

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Circulatory System Cardiac and renal protective

Interventions

dexmedetomidine

placebo

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: ASA class II or III patients scheduled for cardiac surgery by using CPB

Exclusion criteria

Exclusion criteria: age > 75 years, left ventricular ejection fraction (LVEF) < 55%, pre-existing severe LV hypertrophy, cardiomyopathies, grade II (pseudo-normal filling) and grade III (restrictive filling) diastolic dysfunction, preoperative atrial fibrillation , pericardial disease, drug dependence, cerebrovascular diseases, use of alpha 2 agonists ,type 1diabetes mellitus, renal disease, significant pulmonary disease and hepatic insufficiency.

Design outcomes

Primary

Measure	Time frame
myocardial specific protein (troponin-I, creatine phosphokinase-MB "CPK MB") and urinary specific kidney proteins (N- acetyl ¿beta- D glucosamidase, alpha-1-microglobulin, glutathione transferase- pi, glutathione transferase- alpha ). Serum pro-inflammatory cytokines (tumor necrosis factor-¿ and interleukin 1-¿) and norepinephrine and cortisol levels. ;creatinine clearance and serum cystatin	—

Secondary

Measure	Time frame
duration of mechanical ventilation, ICU stay time, hospital stay time, major postoperative complications and 30 day mortality.	—

Countries

Egypt

Contacts

Public Contactkhaled mahmoud

Professor in anesthesiology- Minoufiya faculty of medicine

mahmoudk16@yahoo.com+201223436409

Outcome results

None listed

Source: PACTR (via WHO ICTRP) · Data processed: Aug 9, 2026